Татьяна Ивановна Мещерякова
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Татьяна Ивановна Мещерякова has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ilya V. Kanivets
Genomed LLC, Moscow, Russia
2 shared publications - Nikolay N. Zavadenko
Pirogov Russian National Research Medical University
2 shared publications - Sergey O. Ayvasyan
St. Luka’s Clinical Research Center for Children
2 shared publications - Tatyana V. Kozhanova
Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children; Pirogov Russian National Research Medical University
2 shared publications - Aleksandr A. Abramov
St. Luka’s Clinical Research Center for Children, 119620 Moscow, Russia
1 shared publication - Alexey Koval
Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 90-98
Whole-exome sequencing is the molecular-genetic test of the first-line in developmental and epileptic encephalopathies
Introduction. Developmental and epileptic encephalopathy are severe developmental disorders of the nervous system, characterized by recurrent epileptic seizures that begin over the neonatal period or childhood, accompanied by psychomotor retardation and intellectual disability. Massively parallel sequencing is a technology used to determine the complete nucleotide sequence of DNA or RNA. The technology is characterized by the high productivity and speed, marking the beginning of the golden age of genetics, allowing large volumes of DNA to be sequenced quickly and efficiently at lower costs. The aim of this study is to evaluate the effectiveness of whole- exome sequencing as a first-line genetic test in patients with developmental and epileptic encephalopathy and detect the structure of identified variants in the Russian population. Materials and methods. Patients with drug-resistant seizures, onset in neonatal and early childhood, hospitalized in the Psychoneurological Department during 2017–2023. All patients underwent clinical and genealogical analysis, video-EEG and MRI of the brain, and whole-exome sequencing. Results. The main result obtained in the study analysis of patients who underwent whole exome sequencing for the period of 2017-2023 was the detection rate of variants in genes associated with developmental and epileptic encephalopathy (21.7%; 71/331). Of these, 35/71 (49.3%) had pathogenic and probably pathogenic variants of the nucleotide sequence. Based on the results of whole exome sequencing patients were selected for the most effective targeted antiepileptic drugs. Conclusion. The use of whole-exome sequencing as a first-line molecular genetic test in patients with developmental and epileptic encephalopathy has been shown to be highly effective. Making an accurate genetic diagnosis is a fundamental background for precision therapy. Personalized medicine, that is, the attempt to personalize prevention, diagnosis, and treatment as much as possible according to the characteristics and needs of the patient, should be the main goal of clinical research and a new direction of modern medicine.
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 90-98
Open AccessWhole-exome sequencing is the molecular-genetic test of the first-line in developmental and epileptic encephalopathies
Introduction. Developmental and epileptic encephalopathy are severe developmental disorders of the nervous system, characterized by recurrent epileptic seizures that begin over the neonatal period or childhood, accompanied by psychomotor retardation and intellectual disability. Massively parallel sequencing is a technology used to determine the complete nucleotide sequence of DNA or RNA. The technology is characterized by the high productivity and speed, marking the beginning of the golden age of genetics, allowing large volumes of DNA to be sequenced quickly and efficiently at lower costs. The aim of this study is to evaluate the effectiveness of whole- exome sequencing as a first-line genetic test in patients with developmental and epileptic encephalopathy and detect the structure of identified variants in the Russian population. Materials and methods. Patients with drug-resistant seizures, onset in neonatal and early childhood, hospitalized in the Psychoneurological Department during 2017–2023. All patients underwent clinical and genealogical analysis, video-EEG and MRI of the brain, and whole-exome sequencing. Results. The main result obtained in the study analysis of patients who underwent whole exome sequencing for the period of 2017-2023 was the detection rate of variants in genes associated with developmental and epileptic encephalopathy (21.7%; 71/331). Of these, 35/71 (49.3%) had pathogenic and probably pathogenic variants of the nucleotide sequence. Based on the results of whole exome sequencing patients were selected for the most effective targeted antiepileptic drugs. Conclusion. The use of whole-exome sequencing as a first-line molecular genetic test in patients with developmental and epileptic encephalopathy has been shown to be highly effective. Making an accurate genetic diagnosis is a fundamental background for precision therapy. Personalized medicine, that is, the attempt to personalize prevention, diagnosis, and treatment as much as possible according to the characteristics and needs of the patient, should be the main goal of clinical research and a new direction of modern medicine.
- Open Access
Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease
Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors—the biggest receptor family in metazoans—and play innumerate functions in health and disease. A set of de novo point mutations in GNAO1 and GNAI1, the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in GNAO1 and GNAI1. Here, we describe the case of an infant with another mutation in the same site, Gln52Arg. The patient manifested epileptic and movement disorders and a developmental delay, at the onset of 1.5 weeks after birth. We have analyzed biochemical and cellular properties of the three types of dominant pathogenic mutants in the Gln52 position described so far: Gαo[Gln52Pro], Gαi1[Gln52Pro], and the novel Gαo[Gln52Arg]. At the biochemical level, the three mutant proteins are deficient in binding and hydrolyzing GTP, which is the fundamental function of the healthy G proteins. At the cellular level, the mutants are defective in the interaction with partner proteins recognizing either the GDP-loaded or the GTP-loaded forms of Gαo. Further, of the two intracellular sites of Gαo localization, plasma membrane and Golgi, the former is strongly reduced for the mutant proteins. We conclude that the point mutations at Gln52 inactivate the Gαo and Gαi1 proteins leading to aberrant intracellular localization and partner protein interactions. These features likely lie at the core of the molecular etiology of pediatric encephalopathies associated with the codon 52 mutations in GNAO1/GNAI1.
Open AccessPediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease
Heterotrimeric G proteins are immediate transducers of G protein-coupled receptors—the biggest receptor family in metazoans—and play innumerate functions in health and disease. A set of de novo point mutations in GNAO1 and GNAI1, the genes encoding the α-subunits (Gαo and Gαi1, respectively) of the heterotrimeric G proteins, have been described to cause pediatric encephalopathies represented by epileptic seizures, movement disorders, developmental delay, intellectual disability, and signs of neurodegeneration. Among such mutations, the Gln52Pro substitutions have been previously identified in GNAO1 and GNAI1. Here, we describe the case of an infant with another mutation in the same site, Gln52Arg. The patient manifested epileptic and movement disorders and a developmental delay, at the onset of 1.5 weeks after birth. We have analyzed biochemical and cellular properties of the three types of dominant pathogenic mutants in the Gln52 position described so far: Gαo[Gln52Pro], Gαi1[Gln52Pro], and the novel Gαo[Gln52Arg]. At the biochemical level, the three mutant proteins are deficient in binding and hydrolyzing GTP, which is the fundamental function of the healthy G proteins. At the cellular level, the mutants are defective in the interaction with partner proteins recognizing either the GDP-loaded or the GTP-loaded forms of Gαo. Further, of the two intracellular sites of Gαo localization, plasma membrane and Golgi, the former is strongly reduced for the mutant proteins. We conclude that the point mutations at Gln52 inactivate the Gαo and Gαi1 proteins leading to aberrant intracellular localization and partner protein interactions. These features likely lie at the core of the molecular etiology of pediatric encephalopathies associated with the codon 52 mutations in GNAO1/GNAI1.
- Open Access
- 1 January 2016
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 15 (3) , 301-306
A Clinical and Molecular Description of a Rare Case of Chromosomal Abnormality (Partial Trisomy 14q11.2-q21.1 and Partial Monosomy 21q11.2-q21.3)
Клинико-генетическое описание редкого случая хромосомной аномалии (частичная трисомия 14q11.2-q21.1 в сочетании с частичной моносомией 21q11.2-q21.3)
- 1 January 2016
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 15 (3) , 301-306
Open AccessA Clinical and Molecular Description of a Rare Case of Chromosomal Abnormality (Partial Trisomy 14q11.2-q21.1 and Partial Monosomy 21q11.2-q21.3)
Клинико-генетическое описание редкого случая хромосомной аномалии (частичная трисомия 14q11.2-q21.1 в сочетании с частичной моносомией 21q11.2-q21.3)